Quest Diagnostics has been advancing in various fields. They are developing a
multi-cancer blood test based on technology from MD Anderson. The company's
financial growth is clear. The recent
25.6% stock rally has been attributed to strong revenue growth, and the stock's relative strength rating has been upgraded. The company has also announced its intent to promote more
cancer screenings in collaboration with the University of Texas. Other significant advances include a new blood test that could potentially transform early
cancer detection for nine major types of cancer, showing their commitment to innovation in the medical field.
Working with
Google Cloud, Quest Diagnostics aims to streamline data and personalize customer experiences, employing generative AI. Additionally, they have recently completed the acquisition of the Outreach Lab Services Business of University Hospitals. Their new Alzheimer's blood test reportedly shows promising predictive accuracy. Fresenius Medical Care has divested select lab assets to them, and they have launched health coaching on questhealth.com to help individuals manage their health. The company has reiterated their FY25 guidance, underlining stable future prospects. A recent partnership with Mainz Biomed promises the commercialization of ColoAlert Early Cancer Detection Screening in the U.S.
Quest Diagnostics DGX News Analytics from Wed, 10 Jul 2024 07:00:00 GMT to Fri, 13 Jun 2025 14:13:27 GMT -
Rating 7
- Innovation 8
- Information 7
- Rumor 5
